PMID: 30898075. 80. Hong N, Lee YH, Tsujita K, et al. Comparison of the effects of ezetimibe-statin combination therapy on major adverse cardiovascular events in patients with and without diabetes: A meta-analysis. Endocrinol Metab (Seoul). Jun 2018;33(2):219-227. PMID: 29766679. 81. Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all- cause mortality events. Cochrane Database Syst Rev. Nov 19 2018;11:CD012502. PMID: 30480766. 82. Leiter LA, Tinahones FJ, Karalis DG, et al. Alirocumab safety in people with and without diabetes mellitus: Pooled data from 14 ODYSSEY trials. Diabet Med. Dec 2018;35(12):1742-1751. PMID: 30183102. 83. Harvey PD, Sabbagh MN, Harrison JE, et al. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized phase 2 and 3 controlled trials: A meta-analysis of individual patient data. Eur Heart J. Feb 1 2018;39(5):374-381. PMID: 29186504. 84. Bai J, Gong LL, Li QF, Wang ZH. Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials. J Clin Lipidol. Mar - Apr 2018; 12(2):277-291 e273. PMID: 29428832. 85. Robinson JG, Rosenson RS, Farnier M, et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: Pooled data from randomized trials. J Am Coll Cardiol. Feb 7 2017;69(5):471-482. PMID: 28153102. 86. Schwartz GG, Steg PG, Szarek M, Bhatt DL. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. Nov 29 2018;379(22):2097-2107. PMID: 30403574. 87. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. May 4 2017;376(18):1713-1722. PMID: 28304224. 88. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. Apr 8 2004;350(15):1495-1504. 